New study findings take a step towards the long-sought after diagnostic laboratory test for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), according to NPR. ME/CFS is defined as profound exhaustion that cannot be relieved with sleep and is accompanied with flu-like symptoms, muscle pain, and brain fog. In a recent study, investigators linked ME/CFS to variations in certain cytokines that track with illness severity. The link to gradation in severity rather than seeking a positive versus negative result represents a new approach to identify biological markers of the illness, NPR reported. Included in the study were 192 patients with ME/CFS and 392 healthy controls matched for gender and age. Of the 51 cytokines investigated, only 2 differed in their total concentrations between the 2 groups. However, levels of 17 of the cytokines did vary dramatically between patients with mild versus severe ME/CFS symptoms. According to the report, 13 of 17 cytokines were types that promote inflammation. “This is a field that has been full of skepticism and misconception, where patients have been viewed to have invented their disease,” lead author Dr Jose Montoya told NPR. “These data clearly show the contrary, and demonstrate what can be achieved when we couple good research design with new technology.”
In an effort to pressure members of Congress to revive the repeal law for the Affordable Care Act (ACA), President Donald Trump warned Monday that he could end payments to insurers, according to The Wall Street Journal. Ending federal payments to insurers would allow them to be “hurt” by the ACA, President Trump stated. “If Obamacare is hurting people, and it is, why shouldn’t it hurt the insurance companies,” Trump wrote on Twitter. The tweet alludes to the ACA’s cost-sharing reduction payments, which helps insurers cut deductibles and other costs for low-income consumers.